Zobrazeno 1 - 10
of 21
pro vyhledávání: '"Phyo Than Htoo"'
Autor:
Phyo T. Htoo, Helen Tesfaye, Sebastian Schneeweiss, Deborah J. Wexler, Brendan M. Everett, Robert J. Glynn, Niklas Schmedt, Lisette Koeneman, Anouk Déruaz-Luyet, Julie M. Paik, Elisabetta Patorno
Publikováno v:
Cardiovascular Diabetology, Vol 23, Iss 1, Pp 1-12 (2024)
Abstract Background No randomized clinical trials have directly compared the cardiorenal effectiveness of empagliflozin and GLP-1RA agents with demonstrated cardioprotective effects in patients with a broad spectrum of cardiovascular risk. We reporte
Externí odkaz:
https://doaj.org/article/a409dae7b8d64bffbc67fb3a8cee406b
Autor:
Phyo T. Htoo, Helen Tesfaye, Sebastian Schneeweiss, Deborah J. Wexler, Brendan M. Everett, Robert J. Glynn, Niklas Schmedt, Lisette Koeneman, Anouk Déruaz-Luyet, Julie M. Paik, Elisabetta Patorno
Publikováno v:
Cardiovascular Diabetology, Vol 23, Iss 1, Pp 1-2 (2024)
Externí odkaz:
https://doaj.org/article/1b45064e466d4e25abc84ea3e931b788
Autor:
Phyo T. Htoo, John Buse, Matthew Cavender, Tiansheng Wang, Virginia Pate, Jess Edwards, Til Stürmer
Publikováno v:
Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, Vol 11, Iss 4 (2022)
Background Randomized trials demonstrate the cardioprotective effects of sodium‐glucose cotransporter 2 inhibitors (SGLT2i) and glucagon‐like peptide‐1 receptor agonists (GLP‐1RA). We evaluated their relative cardiovascular effectiveness in r
Externí odkaz:
https://doaj.org/article/eb0234f00cb942098dd47a061512a016
Autor:
Norbert Pötschke, Phyo Than Htoo, Helen Tesfaye, Julie M. Paik, Deborah Wexler, Mehdi Najafzadeh, Robert J Glynn, Anouk Déruaz-Luyet, Soulmaz Fazeli Farsani, Lisette Koeneman, Sebastian Schneeweiss, Elisabetta Patorno
Publikováno v:
Diabetologie und Stoffwechsel.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::99d1ebe62ff6823df6b885f26af12208
https://doi.org/10.1055/s-0043-1767943
https://doi.org/10.1055/s-0043-1767943
Autor:
Phyo T Htoo, Julie M Paik, Ethan Alt, Dae Hyun Kim, Deborah J Wexler, Seoyoung C Kim, Elisabetta Patorno
Publikováno v:
The Journals of Gerontology: Series A.
Background Severe hypoglycemia is associated with adverse clinical outcomes. We evaluated the risk of severe hypoglycemia in older adults initiating newer glucose-lowering medications overall and across strata of known indicators of high hypoglycemia
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::fbcd90eeb821d226c8bcfc3373933f5c
https://doi.org/10.1093/gerona/glad075
https://doi.org/10.1093/gerona/glad075
Autor:
Phyo T. Htoo, Helen Tesfaye, Sebastian Schneeweiss, Deborah J. Wexler, Brendan M. Everett, Robert J. Glynn, Seoyoung C. Kim, Mehdi Najafzadeh, Lisette Koeneman, Soulmaz Fazeli Farsani, Anouk Déruaz-Luyet, Julie M. Paik, Elisabetta Patorno
Publikováno v:
JAMA network open. 5(10)
ImportanceLimited evidence is available on the comparative effectiveness of empagliflozin vs alternative second-line glucose-lowering agents in patients with type 2 diabetes (T2D) receiving routine care who have a broad spectrum of cardiorenal risk.O
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f3c384e1a6685ef507ee2b6ced9db540
https://pubmed.ncbi.nlm.nih.gov/36264574
https://pubmed.ncbi.nlm.nih.gov/36264574
Autor:
PHYO T. HTOO, HELEN TESFAYE, JULIE M. PAIK, DEBORAH J. WEXLER, MEHDI NAJAFZADEH, ROBERT GLYNN, ANOUK DERUAZ-LUYET, SOULMAZ F. FAZELI FARSANI, LISETTE KOENEMAN, SEBASTIAN SCHNEEWEISS, ELISABETTA PATORNO
Publikováno v:
Diabetes. 71
Within the EMPRISE® monitoring program, we evaluated the cardiovascular effectiveness of empagliflozin (EMPA) vs. glucagon-like peptide-1 receptor agonists (GLP1RA) or liraglutide using data from Medicare and 2 U.S. commercial claims databases [2014
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::364ded4a6c5a5cece71dab8f4a0a9a2b
https://doi.org/10.2337/db22-179-or
https://doi.org/10.2337/db22-179-or
Autor:
PHYO T. HTOO, HELEN TESFAYE, JULIE M. PAIK, DEBORAH J. WEXLER, MEHDI NAJAFZADEH, ROBERT GLYNN, ANOUK DERUAZ-LUYET, SOULMAZ F. FAZELI FARSANI, LISETTE KOENEMAN, SEBASTIAN SCHNEEWEISS, ELISABETTA PATORNO
Publikováno v:
Diabetes. 71
EMPRISE is a 5-year monitoring program that evaluates the effectiveness and safety of empagliflozin (EMPA) using Medicare and 2 U.S. commercial claims [2014-20 (2018 for Medicare) ]. We identified 190,226 patients ≥18 years with type 2 diabetes ini
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a1c81c9d50bc0bd1458ab449c85dc5b5
https://doi.org/10.2337/db22-1079-p
https://doi.org/10.2337/db22-1079-p
Autor:
Ross J. Simpson, Phyo T. Htoo, Virginia Pate, Michele Jonsson-Funk, Jennifer L. Lund, Til Stürmer
Publikováno v:
Epidemiology
BACKGROUND: Biologic evidence suggests that angiotensin II may play a role in tumor progression or growth. We compared the short-term colorectal cancer (CRC) risk among initiators of angiotensin converting enzyme inhibitors (ACEI) or angiotensin rece
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c1502f6bba8d209609906112d95d5d4b
https://doi.org/10.1097/ede.0000000000001065
https://doi.org/10.1097/ede.0000000000001065
Autor:
Phyo T Htoo, Gregory Measer, Robert Orr, Justin Bohn, Alfred Sorbello, Henry Francis, Sarah K Dutcher, Austin Cosgrove, Amanda Carruth, Sengwee Toh, Noelle M Cocoros
Publikováno v:
American journal of epidemiology. 191(5)
Observational studies of oseltamivir use and influenza complications could suffer from residual confounding. Using negative control risk periods and a negative control outcome, we examined confounding control in a health-insurance-claims–based stud
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::91ca619c8d0e03f5aa3bd15c00047b81
https://pubmed.ncbi.nlm.nih.gov/35106530
https://pubmed.ncbi.nlm.nih.gov/35106530